Division of Pediatric Cardiology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Division of Pediatric Cardiology, Department of Pediatrics, NewYork-Presbyterian/Morgan Stanley Children's Hospital, Columbia University Irving Medical Center, New York, New York.
Division of Pediatric Cardiology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Semin Thorac Cardiovasc Surg. 2019 Summer;31(2):266-273. doi: 10.1053/j.semtcvs.2018.09.027. Epub 2018 Sep 29.
Pulmonary vein stenosis (PVS) is a rare condition that has been linked to prematurity and congenital heart disease (CHD). Despite these associations, treatment options are limited and outcomes are guarded. We investigated differences in PVS outcomes based on the presence of CHD and prematurity, and risk factors for mortality or lung transplantation in PVS. Single-center retrospective cohort study of patients diagnosed with PVS between January 2005 and May 2016 and identified by ICD codes with chart validation. Cox proportional hazard models assessed risk factors for the composite outcome of mortality or lung transplantation. Ninety-three patients with PVS were identified: 65 (70%) had significant CHD, 32 (34%) were premature, and 14 (15%) were premature with CHD. Sixty-five (70%) underwent a PVS intervention and 42 (46%) underwent ≥2 interventions. Twenty-five subjects (27%) died or underwent lung transplant 5.8 months (interquartile range [IQR] 1.1, 15.3) after diagnosis. There was no difference in age at diagnosis or mortality based on presence of CHD or prematurity. PVS diagnosis before age 6 months and greater than 1 pulmonary vein affected at diagnosis were associated with higher mortality (hazards ratio [HR] 3.4 (95% confidence interval 1.5, 7.5), P = 0.003, and HR 2.1 per additional vein affected (95% confidence interval 1.3, 3.4), P = 0.004, respectively). Survival in children with PVS is poor, independent of underlying CHD or prematurity. Younger age and greater number of veins affected at diagnosis are risk factors for worse outcome. Understanding causal mechanisms and development of treatment strategies are necessary to improve outcomes.
肺静脉狭窄(PVS)是一种罕见的病症,与早产和先天性心脏病(CHD)有关。尽管存在这些关联,但治疗选择有限,预后不佳。我们研究了基于 CHD 和早产的 PVS 结果差异,以及 PVS 患者死亡或肺移植的风险因素。这是一项单中心回顾性队列研究,研究对象为 2005 年 1 月至 2016 年 5 月期间通过 ICD 编码并通过图表验证诊断为 PVS 的患者。Cox 比例风险模型评估了死亡或肺移植复合结果的风险因素。共确定了 93 例 PVS 患者:65 例(70%)存在严重 CHD,32 例(34%)为早产儿,14 例(15%)为合并 CHD 的早产儿。65 例(70%)进行了 PVS 干预,42 例(46%)进行了≥2 次干预。25 名受试者(27%)在诊断后 5.8 个月(四分位距 [IQR] 1.1,15.3)死亡或进行了肺移植。是否存在 CHD 或早产与诊断时的年龄或死亡率均无差异。诊断前年龄<6 个月和诊断时影响超过 1 条肺静脉与更高的死亡率相关(风险比 [HR] 3.4(95%置信区间 1.5,7.5),P=0.003,和 HR 每增加一条受累静脉 2.1(95%置信区间 1.3,3.4),P=0.004)。患有 PVS 的儿童的生存率较低,与潜在的 CHD 或早产无关。诊断时年龄较小和受累静脉数量较多是预后不良的危险因素。了解因果机制和制定治疗策略对于改善预后是必要的。